Cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-16. Anything still debated is marked as such rather than presented as settled.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
== Cause == FECD is a degenerative disease of the corneal endothelium with accumulation of focal outgrowths called guttae (meaning a drop-like appearance) and thickening of Descemet's membrane, leading to corneal edema and loss of vision. The corneal endothelial cell layer and its basement membrane (Descemet's membrane) act as a barrier to hydration of the corneal stroma by aqueous humor and are "pump" cells of the cornea that function to maintain hydration of the cornea at a specific level that maintains corneal stromal clarity through precise spatial arrangement of collagen fibers. In FED, Descemet's membrane is grossly thickened with accumulation of abnormal wide-spaced collagen and numerous guttae. Corneal endothelial cells in end-stage FED are reduced in number and appear attenuated, causing progressive stromal edema (swelling). Progressive endothelial cell loss causes relative influx of aqueous humor into the cornea, leading to swelling (corneal stromal edema), which results in blurred vision. Eventually, the epithelium also becomes edematous, resulting in more severe visual impairment. Focal blisters of epithelial edema ("bullae") may be particularly painful when they burst. The inheritance of FECD is complex and polymorphic such that although inheritance is autosomal dominant there are genetic and environmental modifiers that determine the degree to which members of the same family express the disease. There is reasonable evidence of associations between transcription factor 4 (TCF4) genetic polymorphisms and risk of Fuchs' endothelial dystrophy (FED).
Difficulty staying awake Mental confusion Impaired motor functions Impaired reflexes Impaired coordination Impaired balance Dizziness Respiratory depression Low blood pressure Coma Death Coma can be cyclic, with the individual alternating from a comatose state to a hyper-alert state of consciousness, which occurred in a four-year-old boy who overdosed on clonazepam. The combination of clonazepam and certain barbiturates (for example, amobarbital), at prescribed doses has resulted in a synergistic potentiation of the effects of each drug, leading to serious respiratory depression. Overdose symptoms may include extreme drowsiness, confusion, muscle weakness, and fainting.
According to a Pew Research poll, 49% of Americans opposed the bill, 29% were in favor of the bill, and 21% were unsure. According to an IPSOS-Washington Post poll, 42% of Americans opposed the bill, 23% were in favor of the bill, and 23% were unsure. According to a Fox News poll, 59% of Americans opposed the bill, 29% were in favor. According to KFF, 64% of Americans opposed the bill, 35% were in favor. NPR noted that the bill's passage fulfilled several of Trump's campaign promises, but also violated his promise not to touch Medicaid benefits. CNN described its passage as made possible despite intraparty opposition as an example of "Trump's iron grip on his own party" and an "omnipresent" effort to get Republicans on board despite its unpopularity with the American public. In June 2026, nearly one year after the bill's passage, a Navigator Research poll found that 34% of Americans approved of the law, 53% disapproved, and 13% were unsure.
Along their route, they visited cocoa and sugar cane plantations—operations that, much to Humboldt’s dismay, were still worked by enslaved laborers. In these cultivated areas, Humboldt studied water management issues. He observed that deforestation had interrupted the natural water cycle: the loss of forests as reservoirs led to severe soil desiccation under the relentless sun. At Lake Valencia, he recognized that the lake’s water level had once been higher and warned that continued settlement and irrigation would cause further decline—a prediction since borne out, as the lake has lost a third of its volume. He also took a keen interest in the municipal systems of the settlements, criticizing the Spanish colonial policy that stifled local self-government and, in his view, suppressed economic development. Despite these structural problems, the travelers, armed with letters of recommendation, received warm welcomes in each village and town. One of Humboldt’s most memorable encounters in the Aragua valleys was with the remarkable palo de vaca or cow tree (also called “arbol de leche,” the milk tree), a species previously unknown to European science. Although the tree resembled the unremarkable star apple, it possessed an extraordinary quality: when its trunk was cut, it oozed a thick, fragrant, drinkable sap—essentially, plant milk. Humboldt and Bonpland sampled this sap without ill effect and watched as the indigenous people tapped the trees at sunrise, collecting the milk in bowls to drink or carry home.
== Other products produced == The main products of malolactic fermentation are lactic acid, diacetyl, acetic acid, acetoin, and various esters. The amount and exact nature of these products depends on the species/strain of LAB conducting the malolactic fermentation and the condition influencing that wine (pH, available nutrients, oxygen levels, etc.). Some strains of O. oeni can synthesize higher alcohols which can contribute to fruity notes in the aroma of the wine. Additionally, some strains of the bacterium have beta-glucosidase enzymes that can break down monoglucosides which are aroma compounds attached to a sugar molecule. When the sugar component is cleaved, the rest of the compound becomes volatilized, meaning it can potentially be detected in the aroma bouquet of the wine. In the early 21st century, some strains of O. oeni were shown to use acetaldehyde by breaking it down into ethanol or acetic acid. While this may help for wines with excessive levels of acetaldehyde, for red wines, it can also destabilize the color of the wine by interfering with acetaldehyde's reaction with anthocyanins to create polymeric pigments that help create a wine's color.
Sources: en.wikipedia.org
=== DNA damage and cellular stress === CK1δ can be also activated by genotoxic stress and DNA damage in a p53-dependent manner, and phosphorylate key regulatory proteins in response to these processes. CK1δ phosphorylates human p53 on Ser-6, Ser-9, and Ser-20. Moreover, CK1δ phosphorylates p53 on Thr-18, once p53 is already phospho-primed, permitting a lower p53-Mdm2 binding and higher p53 activity. Under normal conditions, CK1δ can phosphorylate Mdm2 on Ser-240, Ser-242, Ser-246, and Ser-383, permitting higher p53-Mdm2 stability and further p53 degradation. On the contrary, after DNA damage, ATM phosphorylates CK1δ, which can subsequently phosphorylate Mdm2 inducing its proteasomal degradation. Under hypoxia, CK1δ is involved in reducing cell proliferation by interfering with HIF-1α/ARNT complex formation. Additionally, the activity of topoisomerase II α (TOPOII-α), one of the main regulators of DNA replication, results increased after its CK1δ-mediated phosphorylation on Ser-1106. Under stress conditions, CK1δ can interfere with DNA replication. In fact, CK1δ phosphorylates a main regulator of DNA methylation, the ubiquitin-like containing PHD and RING finger domains 1 protein (UHRF1), on Ser-108, increasing its proteasomal degradation.
Spironolactone is rapidly and extensively metabolized in the liver upon oral administration and has a very short terminal half-life of 1.4 hours. The major metabolites of spironolactone are 7α-thiomethylspironolactone (7α-TMS), 6β-hydroxy-7α-thiomethylspironolactone (6β-OH-7α-TMS), and canrenone (7α-desthioacetyl-δ6-spironolactone). These metabolites have much longer elimination half-lives than spironolactone of 13.8 hours, 15.0 hours, and 16.5 hours, respectively, and are responsible for the therapeutic effects of the medication. As such, spironolactone is a prodrug. The 7α-thiomethylated metabolites of spironolactone were not known for many years and it was originally thought that canrenone was the major active metabolite of the medication, but subsequent research identified 7α-TMS as the major metabolite. Other known but more minor metabolites of spironolactone include 7α-thiospironolactone (7α-TS), which is an important intermediate to the major metabolites of spironolactone, as well as the 7α-methyl ethyl ester of spironolactone and the 6β-hydroxy-7α-methyl ethyl ester of spironolactone. Spironolactone is hydrolyzed or deacetylated at the thioester of the C7α position into 7α-TS by carboxylesterases. Following formation of 7α-TS, it is S-oxygenated by flavin-containing monooxygenases to form an electrophilic sulfenic acid metabolite. This metabolite is involved in the CYP450 inhibition of spironolactone, and also binds covalently to other proteins. 7α-TS is also S-methylated into 7α-TMS, a transformation catalyzed by thiol S-methyltransferase.
=== Cellular energy production === The conversion of ATP to ADP is the principal mechanism for energy supply in biological processes. Energy is produced in cells when the terminal phosphate group in an ATP molecule is removed from the chain to produce adenosine diphosphate (ADP) when water hydrolyzes ATP: ATP + H2O → ADP + HPO42- + H+ + energy However, removing a phosphate group from ADP to produce adenosine monophosphate (AMP) also produces extra energy.
Some interpretations of quantum mechanics claim that observed energy tends to increase when the Born rule is applied due to localization of the wave function. If true, objects could be expected to spontaneously heat up; thus, such models are constrained by observations of large, cool astronomical objects as well as the observation of (often supercooled) laboratory experiments. Milton A. Rothman wrote that the law of conservation of energy has been verified by nuclear physics experiments to an accuracy of one part in a thousand million million (1015). He then defines its precision as "perfect for all practical purposes".
==== During transplantation ==== While during infection T cell exhaustion can develop following persistent antigen exposure after graft transplant similar situation arises with alloantigen presence. It was shown that T cell response diminishes over time after kidney transplant. These data suggest T cell exhaustion plays an important role in tolerance of a graft mainly by depletion of alloreactive CD8 T cells. Several studies showed positive effect of chronic infection on graft acceptance and its long-term survival mediated partly by T cell exhaustion. It was also shown that recipient T cell exhaustion provides sufficient conditions for NK cell transfer. While there are data showing that induction of T cell exhaustion can be beneficial for transplantation it also carries disadvantages among which can be counted increased number of infections and the risk of tumor development.
Sources: en.wikipedia.org
Casualty numbers have escalated significantly over time. According to a Stratfor report, the number of drug-related deaths in 2006 and 2007 (2,119 and 2,275) more than doubled to 5,207 in 2008. The number further increased substantially over the next two years, from 6,598 in 2009 to over 11,000 in 2010. According to data from the Mexican government, the death numbers are even higher: 9,616 in 2009, 15,273 in 2010, coming to a total of 47,515 killings between 2006 and January 2012. It is often not clear what deaths are part of the Mexican drug war versus general criminal homicides, and different sources give different estimates. Casualties are often measured indirectly by estimated total deaths from organized crime in Mexico. This amounts to about 115,000 people in the years 2007–2018. From 2018 to 2020, it was estimated that there were 11,400 reports of gang violence, and over 80% of the attacks targeted civilians, resulting in 13,000 related deaths during the period.
guanylyl cyclase-A (GC-A) also known as natriuretic peptide receptor-A (NPRA/ANPA) or NPR1 guanylyl cyclase-B (GC-B) also known as natriuretic peptide receptor-B (NPRB/ANPB) or NPR2 natriuretic peptide clearance receptor (NPRC/ANPC) or NPR3 NPR-A and NPR-B have a single membrane-spanning segment with an extracellular domain that binds the ligand. The intracellular domain maintains two consensus catalytic domains for guanylyl cyclase activity. Binding of a natriuretic peptide induces a conformational change in the receptor that causes receptor dimerization and activation. The binding of ANP to its receptor causes the conversion of GTP to cGMP and raises intracellular cGMP. As a consequence, cGMP activates a cGMP-dependent kinase (PKG or cGK) that phosphorylates proteins at specific serine and threonine residues. In the medullary collecting duct, the cGMP generated in response to ANP may act not only through PKG but also via direct modulation of ion channels. NPR-C functions mainly as a clearance receptor by binding and sequestering ANP from the circulation. All natriuretic peptides are bound by the NPR-C.
Etodesnitazene (also known as desnitroetonitazene, etazen, etazene, and etazone) is a benzimidazole-derived opioid analgesic drug, which was originally developed in the late 1950s alongside etonitazene and a range of related derivatives. It is many times less potent than etonitazene itself, but still 70 times more potent than morphine in animal studies. Corresponding analogues where the N,N-diethyl group is replaced by piperidine or pyrrolidine rings also retain significant activity (10 times and 20 times morphine, respectively). Etodesnitazene has been sold as a designer drug, first being identified in both Poland and Finland in March 2020.
==== Freeze-drying ==== Freeze-drying, also known as freeze-casting or ice-templating, offers an alternative to the high temperature and high-pressure requirements of supercritical drying. Additionally, freeze-drying offers more control of the solid structure development by controlling the ice crystal growth during freezing. In this method, a colloidal dispersion of the aerogel precursors is frozen, with the liquid component freezing into different morphologies depending on a variety of factors such as the precursor concentration, type of liquid, temperature of freezing, and freezing container. As this liquid freezes, the solid precursor molecules are forced into the spaces between the growing crystals. Once completely frozen, the frozen liquid is sublimed into a gas through lyophilization, which removes much of the capillary forces, as was observed in supercritical drying. Though typically classified as a "cryogel", aerogels produced through freeze-drying often experience some shrinkage and cracking while also producing a non-homogenous aerogel framework. This often leads to freeze-drying being used for the creation of aerogel powders or as a framework for composite aerogels.
=== Investment === Investment in dedicated UK AI companies rebounded to £2.9 billion in 2024, surpassing the previous record of £2.4 billion set in 2022 and recovering strongly from a trough of £1.5 billion in 2023. The average deal size rose to approximately £5.9 million in 2024, compared to £4.6 million in 2022. International investors, including Microsoft, Nvidia, and SoftBank, continue to provide the largest investment contributions. In 2024, there were 51 AI-related inward investment projects into the UK, representing over £15 billion in capital investment and expected to create more than 6,500 jobs. These were dominated by infrastructure investments from Amazon, Google, CoreWeave, and Vantage Data Centres. Despite this growth, qualitative research conducted for the Sector Study identified a persistent "scale-up gap": the UK is described as "very good at the start phase, but [at] the scale up phase (beyond Series A), there's a missing piece there". More than half of dedicated AI companies identified in 2024 are at the seed stage of development, showing a healthy start-up scene, but investors cited a lack of larger-scale growth capital, risk aversion among existing UK investors, and insufficient uptake of pension fund investment in venture capital as key structural barriers.
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.